Facing skepticism from analysts…
Facing skepticism from analysts about whether it has the resources [...]
Novartis may have signed off on…
Novartis may have signed off on the second-largest pharma acquisition [...]
After laying off 80% of staffers…
After laying off 80% of staffers this spring, Tempest Therapeutics [...]
Korea’s Celltrion is continuing…
Korea’s Celltrion is continuing to move beyond biosmilars, this time [...]
GSK has paid $50 million upfront…
GSK has paid $50 million upfront to partner with LTZ [...]
On its face, there wasn’t much…
On its face, there wasn’t much notable about Biogen’s May [...]
Vanda Pharmaceuticals’ expansion…
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared [...]
Genmab has shed another…
Genmab has shed another antibody-drug conjugate from its April 2024 [...]
After laying off most of its staff…
After laying off most of its staff and partnering away [...]
Bayer has built a home for Chinese…
Bayer has built a home for Chinese biopharma companies. Located [...]